Mantle cell lymphoma: Observation to transplantation

Babak Rajabi, John W. Sweetenham

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Mantle cell lymphoma as a rare non-Hodgkin B-cell lymphoma can present in different clinical presentations such as an aggressive form or a more indolent picture. Treatment modality is based on multiple factors including age, presence or absence of symptoms, and comorbidities. Watchful waiting is a reasonable approach for asymptomatic patients especially in elderly. In symptomatic patients, treatment is chemo-immunotherapy followed by maintenance immunotherapy or autologous bone marrow transplant. Allogeneic bone marrow transplant has a potential benefit of cure for relapsed/refractory cases, but it has a high mortality rate. Novel treatment with agents such as ibrutinib, a Bruton tyrosine kinase inhibitor, has shown promising results in relapse/refractory cases. We extensively review the most recent data on diagnostic and therapeutic management of mantle cell lymphoma through presenting two extreme clinical scenarios.

Original languageEnglish (US)
Pages (from-to)37-48
Number of pages12
JournalTherapeutic Advances in Hematology
Volume6
Issue number1
DOIs
StatePublished - Feb 2015
Externally publishedYes

Fingerprint

Mantle-Cell Lymphoma
Transplantation
Observation
Immunotherapy
Bone Marrow
Watchful Waiting
Transplants
Age Factors
B-Cell Lymphoma
Therapeutics
Non-Hodgkin's Lymphoma
Comorbidity
Maintenance
Recurrence
Mortality

Keywords

  • chemo-immunotherapy
  • ibrutinib
  • mantle cell lymphoma
  • transplantation

ASJC Scopus subject areas

  • Hematology

Cite this

Mantle cell lymphoma : Observation to transplantation. / Rajabi, Babak; Sweetenham, John W.

In: Therapeutic Advances in Hematology, Vol. 6, No. 1, 02.2015, p. 37-48.

Research output: Contribution to journalReview article

@article{f8f1903f55ea4e6197ecd98509c1ae19,
title = "Mantle cell lymphoma: Observation to transplantation",
abstract = "Mantle cell lymphoma as a rare non-Hodgkin B-cell lymphoma can present in different clinical presentations such as an aggressive form or a more indolent picture. Treatment modality is based on multiple factors including age, presence or absence of symptoms, and comorbidities. Watchful waiting is a reasonable approach for asymptomatic patients especially in elderly. In symptomatic patients, treatment is chemo-immunotherapy followed by maintenance immunotherapy or autologous bone marrow transplant. Allogeneic bone marrow transplant has a potential benefit of cure for relapsed/refractory cases, but it has a high mortality rate. Novel treatment with agents such as ibrutinib, a Bruton tyrosine kinase inhibitor, has shown promising results in relapse/refractory cases. We extensively review the most recent data on diagnostic and therapeutic management of mantle cell lymphoma through presenting two extreme clinical scenarios.",
keywords = "chemo-immunotherapy, ibrutinib, mantle cell lymphoma, transplantation",
author = "Babak Rajabi and Sweetenham, {John W.}",
year = "2015",
month = "2",
doi = "10.1177/2040620714561579",
language = "English (US)",
volume = "6",
pages = "37--48",
journal = "Therapeutic Advances in Hematology",
issn = "2040-6207",
number = "1",

}

TY - JOUR

T1 - Mantle cell lymphoma

T2 - Observation to transplantation

AU - Rajabi, Babak

AU - Sweetenham, John W.

PY - 2015/2

Y1 - 2015/2

N2 - Mantle cell lymphoma as a rare non-Hodgkin B-cell lymphoma can present in different clinical presentations such as an aggressive form or a more indolent picture. Treatment modality is based on multiple factors including age, presence or absence of symptoms, and comorbidities. Watchful waiting is a reasonable approach for asymptomatic patients especially in elderly. In symptomatic patients, treatment is chemo-immunotherapy followed by maintenance immunotherapy or autologous bone marrow transplant. Allogeneic bone marrow transplant has a potential benefit of cure for relapsed/refractory cases, but it has a high mortality rate. Novel treatment with agents such as ibrutinib, a Bruton tyrosine kinase inhibitor, has shown promising results in relapse/refractory cases. We extensively review the most recent data on diagnostic and therapeutic management of mantle cell lymphoma through presenting two extreme clinical scenarios.

AB - Mantle cell lymphoma as a rare non-Hodgkin B-cell lymphoma can present in different clinical presentations such as an aggressive form or a more indolent picture. Treatment modality is based on multiple factors including age, presence or absence of symptoms, and comorbidities. Watchful waiting is a reasonable approach for asymptomatic patients especially in elderly. In symptomatic patients, treatment is chemo-immunotherapy followed by maintenance immunotherapy or autologous bone marrow transplant. Allogeneic bone marrow transplant has a potential benefit of cure for relapsed/refractory cases, but it has a high mortality rate. Novel treatment with agents such as ibrutinib, a Bruton tyrosine kinase inhibitor, has shown promising results in relapse/refractory cases. We extensively review the most recent data on diagnostic and therapeutic management of mantle cell lymphoma through presenting two extreme clinical scenarios.

KW - chemo-immunotherapy

KW - ibrutinib

KW - mantle cell lymphoma

KW - transplantation

UR - http://www.scopus.com/inward/record.url?scp=84993725154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84993725154&partnerID=8YFLogxK

U2 - 10.1177/2040620714561579

DO - 10.1177/2040620714561579

M3 - Review article

C2 - 25642314

AN - SCOPUS:84993725154

VL - 6

SP - 37

EP - 48

JO - Therapeutic Advances in Hematology

JF - Therapeutic Advances in Hematology

SN - 2040-6207

IS - 1

ER -